IFP Advisors’s Fortress Biotech FBIO Stock Holding History

IFP Advisors’s Portfolio FBIO Stock Details FBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-3	Closed	-$181	–	3111
2021 Q1	$0	Buy	+3	New	+$169	﹤0.01%	3066

Other funds holding FBIO

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

SAM

Shikiar Asset Management New York $396M AUM 41.06% 1-Year Est. Return

CPWM LLC Seattle, Washington $1.06B AUM 14.49% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

IFP Advisors's FBIO Position: Q2 2021 in Review

IFP Advisors sold out of Fortress Biotech (FBIO) in Q2 2021, closing a stake of 3 shares — an estimated $181 sold.

IFP Advisors first reported a position in FBIO in Q1 2021 and held it in 1 quarter. The position peaked at $0 in Q1 2021. 84 funds tracked by Wall St. Rank hold FBIO as of Q2 2021.

IFP Advisors reported no remaining Fortress Biotech position as of Q2 2021 after selling out during the quarter.
IFP Advisors sold 3 Fortress Biotech shares in Q2 2021, an estimated $181.
IFP Advisors first reported a position in Fortress Biotech in Q1 2021 and held it in 1 quarter.
IFP Advisors's Fortress Biotech position peaked at $0 in Q1 2021.
84 funds tracked by Wall St. Rank held Fortress Biotech as of Q2 2021.

Based on IFP Advisors's 13F filing for Q2 2021, filed 13 Jul 2021.